Forecast Of The Day: Merck’s Oncology Drug Sales
What?
Trefis expects Merck (NYSE:MRK) Oncology drug sales to grow from levels of around $16 billion in 2020 to $19 billion in 2021 and $22 billion in 2022.
Why?
- Will Higher Keytruda Sales Drive Merck’s Q1
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
We expect growth to come on the back of higher sales of Merck’s immensely popular immuno-oncology drug, Keytruda.
So What?
Keytruda’s drug patents are protected till 2028, implying that the peak is still far off, enabling Merck to significantly scale up Oncology drug revenues. Approvals for the drug have been expanding beyond its core use in lung cancer. Over 2020, Keytruda saw approvals for use in bladder cancer, skin cancer, colorectal cancer, and classic Hodgkin’s lymphoma.
See Our Complete Analysis For Merck
Looking for a balanced portfolio to invest in? Here’s a high-quality portfolio to beat the market, with over 150% return since 2016, versus 85% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams